Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010270
Filing Date
2025-05-14
Accepted
2025-05-14 16:10:50
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1109348
2 EX-31.1 ex31-1.htm EX-31.1 18544
3 EX-31.2 ex31-2.htm EX-31.2 18463
4 EX-32.1 ex32-1.htm EX-32.1 8955
5 EX-32.2 ex32-2.htm EX-32.2 9131
  Complete submission text file 0001641172-25-010270.txt   5907399

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250331.xsd EX-101.SCH 42889
7 XBRL CALCULATION FILE cycc-20250331_cal.xml EX-101.CAL 45162
8 XBRL DEFINITION FILE cycc-20250331_def.xml EX-101.DEF 234963
9 XBRL LABEL FILE cycc-20250331_lab.xml EX-101.LAB 400378
10 XBRL PRESENTATION FILE cycc-20250331_pre.xml EX-101.PRE 312486
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 871331
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50626 | Film No.: 25945576
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)